Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 502576904

TARGETMOL CHEMICALS INC RELUGOLIX 10MG
SDP

Catalog No. 502576904
Encompass_Preferred

Also available in 1 mg 5 mg 25 mg 50 mg 100 mg 500 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. Relugolix (RVT-601) is an orally available non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. purity: 99%

Catalog No. 50-257-6904 Supplier TARGETMOL CHEMICALS INC Supplier No. T363010MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Also available in 1 mg 5 mg 25 mg 50 mg 100 mg 500 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. Relugolix (RVT-601) is an orally available non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. purity: 99%

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.